Skip to main content

Patient Recruitment

Idiopathic Membranous Nephropathy Study

Smiling woman leaning on box.

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is conducting a pilot intervention study for patients diagnosed with idiopathic membranous nephropathy. The purpose of this study is to evaluate the safety and effectiveness of Rituximab plus Cyclosporine in the treatment of membranous nephropathy. There is no cost for study-related medications or tests received. The study will be conducted at the NIH Clinical Center in Bethesda, Maryland.

To participate in this study patient must:

  • Be an adult at least 18 years of age
  • Have a diagnosis of idiopathic membranous nephropathy
  • Have had a renal biopsy within the past 24 months that shows typical changes of membranous nephropathy

Patients may not be eligible if they have:

  • Received previous treatment with Rituximab
  • Been treated with Cyclosporine for more than 6 months

For more information, please call toll free:
TTY: 1-866-411-1010
Se habla español

Or go online:
Refer to study #09-DK-0223

Department of Health and Human Services
National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases

NOTE: PDF documents require the free Adobe Reader.

This page last updated on 10/22/2021

You are now leaving the NIH Clinical Center website.

This external link is provided for your convenience to offer additional information. The NIH Clinical Center is not responsible for the availability, content or accuracy of this external site.

The NIH Clinical Center does not endorse, authorize or guarantee the sponsors, information, products or services described or offered at this external site. You will be subject to the destination site’s privacy policy if you follow this link.

More information about the NIH Clinical Center Privacy and Disclaimer policy is available at